Alder BioPharmaceuticals to Present at the 16th Annual Needham Healthcare Conference

BOTHELL, Wash., March 28, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast its presentation at the upcoming 16th Annual Needham Healthcare Conference at 5:00 p.m. ET (2:00 p.m. PT) on Tuesday, April 4, 2017 in New York, NY. The presentation will feature a business overview and update by Randall C. Schatzman, Ph.D., president and chief executive officer.

A live audio webcast can be accessed on the Events & Presentations page of the Investors section of Alder’s website at http://www.alderbio.com, or by following the link below in your web browser. An archived replay of the webcast will be available on Alder’s website for 30 days after the live event concludes.

Link: http://wsw.com/webcast/needham80/aldr

About Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc. For more information, please visit http://www.alderbio.com.

Media Contacts:
David Schull or Victoria Meissner
Russo Partners, LLC
(212) 845-4271
(646) 942-5627 
[email protected]
[email protected]

Investor Relations Contact:
David Walsey
Alder Biopharmaceuticals
(425) 408-8032
[email protected]

Source: Alder BioPharmaceuticals, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Monero XMR Price Prediction: XMR Hits $524 as Institutional Privacy Narrative Builds While MemeToro Presale Gains Attention
• Spartacus Announces AGM Results
• GreenCore Solutions Corp. (GSC) AI Agent Stack Passes 24.5 Million Inbound AI Agent Transactions In 30 Days